Is VYNE Therapeutics Inc. (VYNE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.5% / 30% | 310.5% / 30% | 0.0% / 30% | 765.27% / 5% | ✗ NOT HALAL |
| DJIM | 0.5% / 33% | 310.5% / 33% | 0.0% / 33% | 765.27% / 5% | ✗ NOT HALAL |
| MSCI | 0.1% / 33% | 91.9% / 33% | 0.0% / 33% | 765.27% / 5% | ✗ NOT HALAL |
| S&P | 0.5% / 33% | 310.5% / 33% | 0.0% / 33% | 765.27% / 5% | ✗ NOT HALAL |
| FTSE | 0.1% / 33% | 91.9% / 33% | 0.0% / 50% | 765.27% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -4014.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -67.0% | |
| Return on Assets (ROA) | -38.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$33M |
| Total Debt | $0 |
| Current Ratio | 12.5 |
| Total Assets | $30M |
Price & Trading
| Last Close | $0.62 |
| 50-Day MA | $0.59 |
| 200-Day MA | $0.58 |
| Avg Volume | 458K |
| Beta | 2.0 |
|
52-Week Range
$0.28
| |
About VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is VYNE Therapeutics Inc. (VYNE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), VYNE Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is VYNE Therapeutics Inc.'s debt ratio?
VYNE Therapeutics Inc.'s debt ratio is 0.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.1%.
What are VYNE Therapeutics Inc.'s key financial metrics?
VYNE Therapeutics Inc. has a market capitalization of $20M, and revenue of $570,000. Return on equity stands at -67.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.